NASDAQ:SURF Surface Oncology (SURF) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free SURF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.01▼$1.0950-Day Range$0.88▼$1.0852-Week Range$0.56▼$1.43Volume1.51 million shsAverage Volume430,375 shsMarket Capitalization$65.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Surface Oncology alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Surface Oncology Stock (NASDAQ:SURF)Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. SURF Stock News HeadlinesApril 25, 2024 | tmcnet.comMedigene presents streamlined 6-day, high stemness TCR-T therapy production processApril 24, 2024 | msn.comCAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in clinical trialApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 24, 2024 | markets.businessinsider.comBuy Rating on Carisma Therapeutics: Pioneering CAR-M Therapies in Oncology and FibrosisApril 24, 2024 | yahoo.comPalomar Health introduces new cancer imaging machines in San DiegoApril 23, 2024 | msn.comFDA approves immunotherapy drug combo for non-muscle invasive bladder cancerApril 18, 2024 | msn.comMill Creek clinic can now cure some skin cancers without surgeryApril 18, 2024 | finance.yahoo.comPathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into ClinicApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | msn.comGritstone bio (GRTS) Price Target Decreased by 37.04% to 5.78April 17, 2024 | msn.comTargeted therapies outperform hundreds of other drugs in 'priming' lung cancer cells for destructionApril 16, 2024 | finance.yahoo.comCompass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsApril 11, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual MeetingApril 10, 2024 | msn.comLook Up and See the FutureApril 9, 2024 | finance.yahoo.comNotable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024April 9, 2024 | msn.comExtracellular cell matrix stiffness may induce drug resistance of breast cancer cellsApril 9, 2024 | msn.comTargeted Therapy Revolution: For People With Cancers That Have A Special Factor Called HER2, The Drug Enhertu Is Now Approved Across Tumor Types- What To Ask Your DoctorApril 9, 2024 | finance.yahoo.comNvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic MedicinesApril 8, 2024 | businesswire.comOrthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal DeviceApril 6, 2024 | finance.yahoo.comTempus Introduces Workspaces into its Lens Data Analytics PlatformApril 5, 2024 | finance.yahoo.com23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024April 4, 2024 | msn.comIs THIS what's causing mystery rise in colon cancers among young people? New research points to bacteria in the gut linked to processed food and not eating enough fiberApril 4, 2024 | msn.comHow is Metastatic Breast Cancer Treated?April 3, 2024 | benzinga.comAnthony A.. Florence Jr's Net WorthApril 2, 2024 | msn.comInvestigators develop novel treatment for T-cell leukemias and lymphomasApril 2, 2024 | msn.comUsing cryo-shocked tumor cells to fight lung cancerApril 1, 2024 | msn.comKyverna reports first use of KYV-101 for multiple sclerosis treatmentSee More Headlines Receive SURF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SURF CUSIPN/A CIK1718108 Webwww.surfaceoncology.com Phone(617) 714-4096FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,590,000.00 Net MarginsN/A Pretax Margin-211.95% Return on Equity-107.81% Return on Assets-65.57% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$30 million Price / Sales2.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.32Miscellaneous Outstanding Shares60,824,000Free Float53,525,000Market Cap$65.08 million OptionableNot Optionable Beta1.75 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Lisa McGrathChief People OfficerMs. Shannon Rourke DevensSr. VP of Devel. OperationsKey CompetitorsLianBioNASDAQ:LIANTevogen BioNASDAQ:TVGNKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMIkena OncologyNASDAQ:IKNAView All CompetitorsInsidersJessica FeesSold 9,434 sharesTotal: $8,867.96 ($0.94/share)Robert W RossSold 16,713 sharesTotal: $15,710.22 ($0.94/share)Chandra AdamsSold 3,901 sharesTotal: $3,666.94 ($0.94/share) SURF Stock Analysis - Frequently Asked Questions Should I buy or sell Surface Oncology stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares. View SURF analyst ratings or view top-rated stocks. How were Surface Oncology's earnings last quarter? Surface Oncology, Inc. (NASDAQ:SURF) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. The business had revenue of $0.39 million for the quarter. What is Jeff Goater's approval rating as Surface Oncology's CEO? 5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Surface Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA). When did Surface Oncology IPO? Surface Oncology (SURF) raised $84 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO. This page (NASDAQ:SURF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surface Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
